Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial von Jakubowiak, Andrzej J., Griffith, Kent A., Reece, Donna E., Hofmeister, Craig C., Lonial, Sagar, Zimmerman, Todd M., Campagnaro, Erica L., Schlossman, Robert L., Laubach, Jacob P., Raje, Noopur S., Anderson, Tara, Mietzel, Melissa A., Harvey, Colleen K., Wear, Sandra M., Barrickman, Jennifer C., Tendler, Craig L., Esseltine, Dixie-Lee, Kelley, Susan L., Kaminski, Mark S., Anderson, Kenneth C., Richardson, Paul G.

Volltext

Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease von Pierson, Sheila K., Shenoy, Sushila, Oromendia, Ana B., Gorzewski, Alexander M., Langan Pai, Ruth-Anne, Nabel, Christopher Shield, Ruth, Jason R., Parente, Sophia A.T., Arenas, Daniel J., Guilfoyle, Mary, Reddy, Manjula, Weinblatt, Michael, Shadick, Nancy, Bower, Mark, Pria, Alessia Dalla, Masaki, Yasufumi, Katz, Laura, Mezey, Jason, Beineke, Philip, Lee, David, Tendler, Craig, Kambayashi, Taku, Fosså, Alexander, van Rhee, Frits, Fajgenbaum, David C.

Volltext

Craig Tendler: Real-world potential von Nowogrodzki, Anna, Tendler, Craig

Volltext

Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer von KELLER, Alan M, MENNEL, Robert G, MELLARS, Lillian, ALLAND, Leila, TENDLER, Craig, GEORGOULIAS, Vassilis A, NABHOLTZ, Jean-Marc, ERAZO, Aura, LLUCH, Anna, VOGEL, Charles L, KAUFMANN, Manfred, VON MINCKWITZ, Gunther, HENDERSON, I. Craig

Volltext

Remote Monitoring and Data Collection for Decentralized Clinical Trials von Daly, Bobby, Brawley, Otis W, Gospodarowicz, Mary K, Olopade, Olufunmilayo I, Fashoyin-Aje, Lola, Smart, Victoria Wolodzko, Chang, I-Fen, Tendler, Craig L, Kim, Geoffrey, Fuchs, Charles S, Beg, Muhammad Shaalan, Zhang, Lianshan, Legos, Jeffrey J, Duran, Cristina Ortega, Kalidas, Chitkala, Qian, Jing, Finnegan, Justin, Pilarski, Piotr, Keane, Harriet, Shen, Johanna, Silverstein, Amy, Wu, Yi-Long, Pazdur, Richard, Li, Bob T

Volltext

Pegylated Interferon Alfa-2b Treatment for Patients With Solid Tumors: A Phase I/II Study von BUKOWSKI, Ronald, ERNSTOFF, Marc S, GORE, Martin E, NEMUNAITIS, John J, AMATO, Robert, GUPTA, Samir K, TENDLER, Craig L

Volltext

Phase I Study of the Farnesyltransferase Inhibitor Lonafarnib with Paclitaxel in Solid Tumors von KHURI, Fadlo R, GLISSON, Bonnie S, BANGERT, Sandra, THOMPSON, Elizabeth, LU, Charles, WANG, Xue-Mei, SHIN, Dong M, KIES, Merrill S, PAPADIMITRAKOPOULOU, Vali, FOSSELLA, Frank V, KIRSCHMEIER, Paul, BISHOP, W. Robert, KIM, Edward S, WAUN KI HONG, STATKEVICH, Paul, THALL, Peter F, MEYERS, Michael L, HERBST, Roy S, MUNDEN, Reginald F, TENDLER, Craig, YALI ZHU

Volltext

Academic and Private Partnership to Improve Informed Consent Forms Using a Data Driven Approach von Tendler, Craig, Hong, Patricia S., Kane, Conor, Kopaczynski, Christa, Terry, William, Emanuel, Ezekiel J.

Volltext

Predictors of response to anti‐IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data von Morra, Deanna E., Pierson, Sheila K., Shilling, Dustin, Nemat, Sepideh, Appiani, Carlos, Guilfoyle, Mary, Tendler, Craig, Rhee, Frits, Fajgenbaum, David C.

Volltext

Harnessing Real-World Evidence for the Development of Novel Cancer Therapies von Greshock, Joel, Lewi, Martine, Hartog, Bert, Tendler, Craig

Volltext

Driving Diversity and Inclusion in Cancer Drug Development - Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges von Fashoyin-Aje, Lola A, Tendler, Craig, Lavery, Bea, Ghiorghiu, Serban, Gerald, Brittany, Kalidas, Chitkala, Richie, Nicole, Winson, Kathleen, Warren, Nicholas J H, Tellman, Tristen V, Retzlaff, Jon, Foti, Margaret, Pazdur, Richard

Volltext

Global adoption of remote technologies to enable patient-centric oncology clinical trials: Analysis by the Bloomberg New Economy International Cancer Coalition von Daly, Robert Michael, Brawley, Otis W., Gospodarowicz, Mary K., Olopade, Olufunmilayo I., Fashoyin, Ibilola, Wolodzko Smart, Victoria, Chang, I-Fen, Tendler, Craig L., Kim, Geoff, Fuchs, Charles S., Zhang, Lianshan, Legos, Jeffrey J., Duran, Cristina, Kalidas, Chitkala, Qian, Jing, Finnegan, Justin, Pilarski, Piotr, Silverstein, Amy, Wu, Yi-Long, Li, Bob T.

Volltext

Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition von Li, Bob T., Daly, Bobby, Gospodarowicz, Mary, Bertagnolli, Monica M., Brawley, Otis W., Chabner, Bruce A., Fashoyin-Aje, Lola, de Claro, R. Angelo, Franklin, Elizabeth, Mills, Jennifer, Legos, Jeff, Kaucic, Karen, Li, Mark, The, Lydia, Hou, Tina, Wu, Ting-Hui, Albrecht, Bjorn, Shao, Yi, Finnegan, Justin, Qian, Jing, Shahidi, Javad, Gasal, Eduard, Tendler, Craig, Kim, Geoffrey, Yan, James, Morrow, Phuong Khanh, Fuchs, Charles S., Zhang, Lianshan, LaCaze, Robert, Oelrich, Stefan, Murphy, Martin J., Pazdur, Richard, Rudd, Kevin, Wu, Yi-Long

Volltext

Predictors of response to anti‐ IL 6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data von Morra, Deanna E., Pierson, Sheila K., Shilling, Dustin, Nemat, Sepideh, Appiani, Carlos, Guilfoyle, Mary, Tendler, Craig, van Rhee, Frits, Fajgenbaum, David C.

Volltext

Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease von Pierson, Sheila K, Katz, Laura, Nabel, Christopher Sheild, Ruth, Jason R, Diamond, Sheila, Karvir, Hrishikesh, Zhang, Fanyi, Reddy, Manjula P, Guilfoyle, Mary, Tendler, Craig, van Rhee, Frits, Beineke, Philip, Oromendia, Ana B, Fajgenbaum, David C

Volltext

Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease von Fajgenbaum, David C, Pierson, Sheila K, Shilling, Dustin, Gardner, Cooper, Liu, Amy Y, Ziglar, Jasira, Bernstein, Shawnee, Mann, Sarah, Zuckerberg, Jeremy, Lukac, Martin, Jayanthan, Raj Kuhan, Guilfoyle, Mary, Tendler, Craig, Ruth, Jason R, Uldrick, Thomas S, van Rhee, Frits

Volltext

Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease von Shilling, Dustin, Ruth, Jason R, Nabel, Christopher Sheild, Pierson, Sheila K, Guilfoyle, Mary, Tendler, Craig, Reddy, Manjula P, Weinblatt, Michael, Shadick, Nancy, Bower, Mark, Dalla Pria, Alessia, Masaki, Yasufumi, Beineke, Philip, Miljovska, Sofija, Katz, Laura, Shenoy, Sushila, Oromendia, Ana B, Mezey, Jason, Wiser, Jeff, Benbanaste, Jef, Lee, David, Fosså, Alexander, van Rhee, Frits, Fajgenbaum, David C

Volltext

The HIV-1 transactivator protein Tat is a potent inducer of the human DNA repair enzyme β-polymerase von SRIVASTAVA, Deepak K, TENDLER, Craig L, MILANI, Daniela, ENGLISH, Milton A, LICHT, Jonathan D, WILSON, Samuel H

Volltext

Treating cancer with PEG Intron: Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation von BUKOWSKI, Ronald M, TENDLER, Craig, CUTLER, David, ROSE, Esther, LAUGHLIN, Mark M, STATKEVICH, Paul

Volltext

Abnormal cytokine expression in Sézary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies von TENDLER, C. L, BURTON, J. D, JAFFE, J, DANIELPOUR, D, CHARLEY, M, MCCOY, J. P, PITTELKOW, M. R, WALDMANN, T. A

Volltext